Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial Meeting Abstract


Authors: Trojan, J.; Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; Cicin, I.; Bolondi, L.; Klümpen, H. J.; Chan, S. L.; Dadduzio, V.; Milwee, S.; Dubey, S.; Kelley, R. K.; El-Khoueiry, A. B.
Abstract Title: Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial
Meeting Title: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie
Journal Title: Oncology Research and Treatment
Volume: 42
Issue: Suppl. 4
Meeting Dates: 2019 Oct 11-14
Meeting Location: Berlin, Germany
ISSN: 2296-5270
Publisher: S. Karger AG  
Date Published: 2019-10-01
Start Page: 243
Language: English
ACCESSION: WOS:000568159600586
PROVIDER: wos
DOI: 10.1159/000502425
Notes: "Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology" -- Meeting Abstract: V894 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ghassan Abou-Alfa
    576 Abou-Alfa